Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines

Starting soon

Conditions studied: Chronic Myeloid Leukemia, Chronic Myeloid Leukemia - Chronic Phase

In brief

The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines. The main object of the study is to assess the achievement of Major Molecular Response.

Key facts

Study ID

NCT07640750

Run by

Gruppo Italiano Malattie EMatologiche dell'Adulto

People needed

98

Starts

2026-09-01

Expected to finish

2031-12-01

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged ≥ 18 years and no upper age limit;
• Patients with a diagnosis of CML-CP who started treatment with asciminib according to clinical practice - from the date of commercial availability of asciminib - until the end of recruitment period (two years after the first patient included);
• Patients treated with asciminib in second or subsequent lines of therapy (≥2L)
• Patients who provide written informed consent to participate in the study (if applicable).

You may not qualify if…

• None

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.